Drug
VAL-083, Dianhydrogalactitol
VAL-083, Dianhydrogalactitol is a pharmaceutical drug with 5 clinical trials. Historical success rate of 75.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_2
2
40%
Ph phase_3
1
20%
Ph phase_1
2
40%
Phase Distribution
2
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Terminated1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
Trials by Status
terminated120%
withdrawn120%
completed360%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
NCT03050736
terminatedphase_3
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
NCT03149575
completedphase_1
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
NCT01478178
completedphase_2
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
NCT02717962
withdrawnphase_1
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
NCT03281681
Clinical Trials (5)
Showing 5 of 5 trials
NCT03050736Phase 2
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
NCT03149575Phase 3
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
NCT01478178Phase 1
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
NCT02717962Phase 2
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
NCT03281681Phase 1
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5